Prostate Cancer and Erectile Disfunction
A special issue of Uro (ISSN 2673-4397).
Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 14475
Special Issue Editor
Special Issue Information
Dear Colleagues,
Prostate cancer (PCa) is the second most common cancer in males, and it represents the first cause of cancer death for cancer in this population. In the last few years, the incidence of PCa in young men has been increasing as a result of several factors, and this has an important impact on sexual function and quality of life. It is known that PCa treatments such as radical prostatectomy, radiotherapy, and castration therapy impact sexual function with different action mechanisms. However, the psychological distress related to cancer diagnosis, and specifically prostate cancer diagnosis, might add a particular burden on erectile function in a subset of patients that may already have some initial erectile difficulty due to the aging further compromising quality of life. Here I would like to investigate with mini-reviews the state of the art of the following related topics:
- Prostate cancer diagnosis and psychological distress: impact on erectile function;
- Radical prostatectomy and minimally invasive prostate cancer treatment: impact on erectile function;
- Radiotherapy and hormonal treatment: impact on erectile function;
- Rehabilitation after prostate cancer treatment: which is the right program?
- New sexual rehabilitation tools after prostate cancer treatments: an overview.
Dr. Alessandro Tafuri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- prostate cancer treatment
- radiotherapy
- castration therapy
- radical prostatectomy
- erectile disfunction
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.